• Reported GAAP EPS of -$0.26 up 36.59% YoY • Reported revenue of $81.72M up 2.05% YoY • Inogen expects full year 2026 reported revenue in the range of $366M to $373M, reflecting approximately 6% growth from 2025 revenue, and anticipates positive Adjusted EBITDA improvement in 2026.
Bullish
Inogen improved operating loss and Adjusted EBITDA through cost reductions and efficiencies. The company introduced new products, launched a patient portal, and announced a strategic collaboration with Yuwell Medical.
Bearish
Inogen's gross margin decreased due to channel mix, and lower U.S. sales and rentals impacted revenue. Q1 2026 revenue is expected flat due to channel mix, reimbursement shifts, and fewer patients.